MilliporeSigma has expanded its single use cGMP facility with the addition of the Mobius 2000L single-use bioreactor. With this increase in scale, the company can advance recombinant products from cell line development through to late-stage clinical production.   At the point of tech transfer out to a contract manufacturing organization or other facility, clients can also leverage MilliporeSigma’s Provantage Services available worldwide to help mitigate the risks traditionally associated...